Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.00 Consensus Price Target from Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $11.00.

A number of research analysts recently commented on EVAX shares. Wall Street Zen lowered shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Friday, April 24th. JonesTrading began coverage on Evaxion A/S in a research report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price on the stock. Lake Street Capital dropped their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, March 9th. Finally, Maxim Group began coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective on the stock.

Evaxion A/S Stock Up 0.7%

EVAX opened at $4.11 on Wednesday. The stock’s fifty day simple moving average is $4.05 and its 200 day simple moving average is $4.39. Evaxion A/S has a 1-year low of $1.95 and a 1-year high of $12.15. The stock has a market cap of $34.28 million, a PE ratio of -2.80 and a beta of 0.26. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.43). As a group, research analysts expect that Evaxion A/S will post -0.5 earnings per share for the current year.

Institutional Trading of Evaxion A/S

A number of institutional investors have recently bought and sold shares of EVAX. Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S during the 1st quarter worth approximately $146,000. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Evaxion A/S in the first quarter valued at approximately $112,000. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S in the fourth quarter valued at approximately $72,000. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S during the fourth quarter worth approximately $48,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S during the 4th quarter worth $38,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.